Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of polymorphisms of angiogenesis genes with breast cancer.
Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA. Schneider BP, et al. Among authors: radovich m. Breast Cancer Res Treat. 2008 Sep;111(1):157-63. doi: 10.1007/s10549-007-9755-9. Epub 2007 Sep 20. Breast Cancer Res Treat. 2008. PMID: 17891484
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Schneider BP, et al. Among authors: radovich m. J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612. J Clin Oncol. 2008. PMID: 18824714 Free PMC article. Clinical Trial.
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Schneider BP, et al. Among authors: radovich m. Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22. Clin Cancer Res. 2013. PMID: 23340303 Free PMC article. Clinical Trial.
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP. Radovich M, et al. Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606. Oncotarget. 2016. PMID: 27447854 Free PMC article.
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr. Schneider BP, et al. Among authors: radovich m. Clin Cancer Res. 2017 Jan 1;23(1):43-51. doi: 10.1158/1078-0432.CCR-16-0908. Epub 2016 Dec 19. Clin Cancer Res. 2017. PMID: 27993963 Free PMC article.
87 results